Your browser doesn't support javascript.
Impact of COVID-19 on cancer screening in South Korea.
Lee, Kyeonmin; Lee, Yun Yeong; Suh, Mina; Jun, Jae Kwan; Park, Bomi; Kim, Yeol; Choi, Kui Son.
  • Lee K; National Cancer Center, Graduate School of Cancer Science and Policy, 323, Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do, 10408, Korea.
  • Lee YY; National Cancer Center, National Cancer Control Institute, Goyang, Gyeonggi-do, Korea.
  • Suh M; National Cancer Center, National Cancer Control Institute, Goyang, Gyeonggi-do, Korea.
  • Jun JK; National Cancer Center, National Cancer Control Institute, Goyang, Gyeonggi-do, Korea.
  • Park B; Department of Preventive Medicine, College of Medicine, Chung-Ang University, Seoul, Korea.
  • Kim Y; National Cancer Center, National Cancer Control Institute, Goyang, Gyeonggi-do, Korea.
  • Choi KS; National Cancer Center, Graduate School of Cancer Science and Policy, 323, Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do, 10408, Korea. kschoi@ncc.re.kr.
Sci Rep ; 12(1): 11380, 2022 07 05.
Article in English | MEDLINE | ID: covidwho-1921722
ABSTRACT
The coronavirus disease (COVID-19) pandemic significantly declined cancer screening rates worldwide. Its impact on the South Korean population is unclear, depending on socioeconomic status (SES), residence, and history of chronic disease. This study utilized data (2018-2020) from the Korean National Cancer Screening Survey, an annual cross-sectional study employing nationally representative random sampling. Cancer screening rates were defined as the proportion of the eligible population who received respective cancer screening within the last 1 year and investigated four major cancers (stomach, colorectal, breast, and cervical). Screening rates every year were compared with screening rate ratios (SRRs) and the corresponding 95% confidence intervals (CIs). Between 2019 and 2020, screening rates declined significantly by 23%, 17%, 12%, and 8% for colorectal cancer (SRR 0.77; 95% CI 0.73-0.82), stomach cancer (SRR 0.83; 95% CI 0.79-0.87), breast cancer (SRR 0.88; 95% CI 0.82-0.93), and cervical cancer (SRR 0.92; 95% CI 0.87-0.97), respectively. Regardless of cancer type, screening was significantly lower in metropolitan residents, those with higher SES, and, interestingly, those without a history of chronic diseases. The significant decline in cancer screening during the pandemic requires urgent political intervention to reduce the burden of future cancer incidence and mortality.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Uterine Cervical Neoplasms / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Female / Humans Country/Region as subject: Asia Language: English Journal: Sci Rep Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Uterine Cervical Neoplasms / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Female / Humans Country/Region as subject: Asia Language: English Journal: Sci Rep Year: 2022 Document Type: Article